Dupilumab, with or without topical corticosteroids, improved atopic dermatitis (AD) signs, symptoms, and quality of life in adults ≥ 60 years of age.

Dupilumab efficacy in patients ≥ 60 years of age was generally consistent with that seen in patients < 60 years of age; safety findings were consistent with the known dupilumab safety profile.

In both age groups, dupilumab significantly reduced the AD biomarkers thymus and activation-regulated chemokine and immunoglobulin E compared with placebo.